Endo CEO Distances Himself From Valeant Amid Specialty Pharmacy Controversy

Amid controversy over specialty pharmacy Philidor improperly changing prescriptions for cheap generic drugs to Valeant’s more expensive branded drugs, Endo CEO Rajiv De Silva attempted to distance himself from Valeant, his former employer.

De Silva, who served as president of Valeant from 2010 to 2013 and as its COO of special pharmaceuticals from 2009 until 2013, told analysts during an earnings call last week that only about 3 percent of Endo's sales go through specialty pharmacies. He said the specialty pharmacies the company uses either are independent or part of other companies.